June 10, 2024

LEAP-001: Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets

The highly anticipated ENGOT-en9/LEAP-001 trial in endometrial cancer has missed both its primary endpoints. At the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer, the st...

May 09, 2024

For Detection of Measurable Residual Disease in Ovarian Cancer, Are Two Methods Better Than One?

In patients with ovarian cancer, second-look surgery may find a role again. The evaluation of measurable residual disease (MRD) using second-look laparoscopy identified more women who had detectable M...

May 09, 2024

DUO-E Trial: Results Support New Treatment Options in Endometrial Cancer

New research findings have highlighted the importance of personalized treatment approaches with the monoclonal antibody durvalumab based on mismatch repair (MMR) status in newly diagnosed patients wi...

May 09, 2024

DUO-E Trial: Results Support New Treatment Options in Endometrial Cancer

New research findings have highlighted the importance of personalized treatment approaches with the monoclonal antibody durvalumab based on mismatch repair (MMR) status in newly diagnosed patients wi...

April 25, 2024

Activity Shown for Antibody-Drug Conjugates in Gynecologic Cancers

The recent approval of mirvetuximab soravtansine-gynx is a testament to the emerging benefit of antibody-drug conjugates in recurrent ovarian cancer. Other agents of this class are now eliciting excit...

April 25, 2024

Expert Point of View: Gini F. Fleming, MD

April 25, 2024

Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer

The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced ovarian cancer with BRCA wild-type, homologous...

April 25, 2024

Expert Point of View: Gini F. Fleming, MD

April 25, 2024

Survival Benefit Emerges With Use of Dostarlimab-gxly Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer

The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced or recurrent endometrial cancer not only reduced the risk of disease progression but improved overal...

April 25, 2024

Activity Shown for Antibody-Drug Conjugates in Gynecologic Cancers

The recent approval of mirvetuximab soravtansine-gynx is a testament to the emerging benefit of antibody-drug conjugates in recurrent ovarian cancer. Other agents of this class are now eliciting excit...

March 26, 2024

Dostarlimab-Based Combinations in Advanced Endometrial Cancer

Statistically significant and clinically meaningful overall survival and progression-free survival results from the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced ...

March 26, 2024

Dostarlimab-Based Combinations in Advanced Endometrial Cancer

Statistically significant and clinically meaningful overall survival and progression-free survival results from the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced ...

March 20, 2024

Avelumab Plus Axitinib in Mismatch Repair–Proficient Recurrent or Persistent Endometrial Cancer

The combination of avelumab and axitinib may be effective in patients with mismatch repair–proficient recurrent or persistent endometrial cancer, according to findings presented at the Society of Gyne...

March 19, 2024

ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer

The AI-based chatbot ChatGPT may correctly answer a majority of the common genetic counseling questions related to gynecologic oncology, according to new findings presented at the Society of Gynecolog...

March 19, 2024

Durvalumab-Based Regimens Improve Response Over Chemotherapy Alone in pMMR Advanced Endometrial Cancer

Latest analysis of the results from the phase III DUO-E trial showed durvalumab plus platinum-based chemotherapy followed by durvalumab plus olaparib demonstrated an improvement in multiple key second...

March 19, 2024

Durvalumab-Based Regimens Improve Response Over Chemotherapy Alone in pMMR Advanced Endometrial Cancer

Latest analysis of the results from the phase III DUO-E trial showed durvalumab plus platinum-based chemotherapy followed by durvalumab plus olaparib demonstrated an improvement in multiple key second...

March 19, 2024

ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer

The AI-based chatbot ChatGPT may correctly answer a majority of the common genetic counseling questions related to gynecologic oncology, according to new findings presented at the Society of Gynecolog...